Agenus AGEN centered its investment case on botensilimab plus balstilimab (BOT+BAL), a checkpoint combination being advanced in refractory microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic ...

AI and chip stocks tanked on Friday, sending the Nasdaq tumbling 4%. The bulls could dig their heels in again early next week. But there’s ...

Here’s a quick recap of the crypto landscape for Wednesday (June 3) as of 8:00 p.m. UTC. Get the latest insights on Bitcoin, Ether and ...

Agenus AGEN sits at a classic biotech crossroads. On one side is BOT+BAL, a lead immuno-oncology program being tested in a late-stage setting where current ...

A lesson from the internet boom could help investors spot the next wave of AI winners. Listen to the audio version of this article (generated ...

Key Points After surging higher for several straight weeks, Ford Motor (NYSE: F) stock is giving back some of those gains this week. As of ...

Agenus AGEN is taking an uncommon route to validate demand for its lead immuno-oncology combination, botensilimab plus balstilimab (BOT+BAL), before a traditional launch. Instead of ...

Cathie Wood is trying to get back on track since blowout returns in 2020 that made her one of the most widely followed growth stock ...

ICON plc ICLR is moving through a credibility and earnings reset that is now as much about controls as it is about demand. The company ...

Key Points Musk reiterated his promise to eat a Happy Meal on live TV if McDonald’s accepted Dogecoin. But its other big mainstream payment deals ...